{"filings":[{"id":609436,"accession_number":"0001193125-26-236869","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2026-05-22T20:08:11+00:00","items":["7.01","9.01"],"status":"ready","headline":"Accendra Health launches exchange offer for 4.5%/6.625% notes; new 9%/9.75% secured notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offer to exchange $478.7M of 4.500% 2029 notes and $552.2M of 6.625% 2030 notes for secured notes.","New 9.000% First Lien Notes due 2032 and 9.750% Second Lien Notes due 2033; $326.25M new money issuance.","Backstop parties commit to buy up to $261M plus $65.25M of First Lien Notes; 3.5% cash premium.","Consent solicitations seek to eliminate substantially all affirmative/negative covenants and certain defaults.","Offers expire June 22, 2026; early exchange deadline June 9, 2026; withdrawal deadline same as early exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452966,"accession_number":"0001104659-26-061888","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2026-05-15T12:30:13+00:00","items":["5.02","5.07"],"status":"ready","headline":"Accendra shareholders elect six directors, ratify KPMG, approve 2023 incentive plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with votes for ranging from 48.8M to 51.2M; broker non-votes 9.8M.","KPMG ratified as auditor for FY 2026 with 61.3M for, 0.7M against.","Advisory say-on-pay passed with 48.1M for, 4.1M against (excluding 9.8M broker non-votes).","Amended and restated 2023 Omnibus Incentive Plan approved with 50.6M for, 1.6M against.","Approximately 81.3% of outstanding shares voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98681,"accession_number":"0001193125-26-215654","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Accendra Health launches $326.25M 9% first lien notes, $300M revolver, and exchange offers for existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $326.25M 9.000% Senior Secured First Lien Notes due 2032 and $300M revolver due 2030.","Exchange offers for all 4.500% 2029 Notes and 83% of 6.625% 2030 Notes; backstop parties commit to purchase up to $261M of new notes.","Consent solicitations to eliminate most covenants and modify defaults; new 9.750% Second Lien Notes due 2033 also offered.","Transactions expected to close by June 30, 2026; proceeds used to repay existing term loan A and revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98680,"accession_number":"0001104659-26-058226","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $627.8M (down 6.8% YoY); GAAP loss from cont. ops $6.5M vs $3.8M loss prior year.","Adjusted EBITDA $58.4M vs $96.0M prior year; free cash flow ($2.0M).","Announces comprehensive >$1.5B balance sheet optimization with existing creditors to extend maturities and reduce leverage.","Transaction expected to pay off 2027 maturities, extend revolver, and reduce total leverage.","CEO says transformation into pure-play home-based care company on track; Owens & Minor separation proceeding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":627780000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114295,"accession_number":"0001104659-26-017541","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).","GAAP loss from continuing ops improved to $9.4M from $331.9M in Q4 2024.","Adjusted net income $16.7M ($0.21/share) vs $25.0M ($0.32) prior year.","Adj. EBITDA $90M vs $102.5M; free cash flow $18.3M vs $30.1M.","Completed sale of Products & Healthcare Services on Dec 31, 2025; focusing on cost control and balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2762032000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114294,"accession_number":"0001104659-26-000614","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K/A","filed_at":"2026-01-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.","Pro forma 2024 revenue $2.68B (vs $10.7B reported); net loss pro forma $366.5M vs $362.7M.","Pro forma diluted EPS: 2024 -$4.78, 2023 -$0.15, 2022 -$0.72.","Amended Receivables Sale Program: sold $94M eligible receivables, removed $160M intercompany payable.","Retained a 5% equity interest in buyer with potential for up to $200M of priority distributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130674,"accession_number":"0001193125-25-338325","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","2.01","2.03","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Owens & Minor completes $375M sale of P&HS segment to Platinum Equity; will rename to Accendra Health","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed for $375M cash, plus 5% retained equity and preserved tax attributes >$150M.","Company renamed Accendra Health, Inc.; new ticker ACH starts Jan 2, 2026.","EVP Andrew G. Long (CEO P&HS) and CAO Michael W. Lowry depart; CFO Jonathan Leon assumes principal accounting officer.","Entered $150M receivables sale program with PNC; proceeds for general corporate purposes.","Former credit facilities and indentures partially released for sold entities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130673,"accession_number":"0001104659-25-122553","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor to rename as Accendra Health; ticker changes to ACH on Jan 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Accendra Health, Inc. effective Dec 31, 2025; NYSE ticker becomes \"ACH\" on Jan 2, 2026.","CEO says rebranding reflects strategic shift to pure-play home-based care; Apria and Byram brands continue.","Board froze Executive Deferred Compensation and Retirement Plan effective Jan 1, 2026, halting participation and contributions.","No shareholder action required; CUSIP unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130672,"accession_number":"0001193125-25-310528","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Appoints Perry A. Bernocchi as COO effective Dec 5; CHRO Stone to depart Dec 31, role eliminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Perry A. Bernocchi, age 67, appointed EVP, COO effective Dec 5, 2025; previously led Patient Direct segment.","Bernocchi's compensation unchanged; no reportable transactions or family relationships.","Jennifer Stone, EVP CHRO, to leave Dec 31, 2025; CHRO position eliminated.","Heath Galloway, EVP GC & Corp Sec, will oversee HR function after Stone's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130671,"accession_number":"0001193125-25-304500","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Owens & Minor management to present at Citi and BofA conferences on Dec 2, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Ed Pesicka (CEO) and Will Parrish (VP) to speak at Citi 2025 Global Healthcare Conference on Dec 2.","Jon Leon (CFO) and Alex Miller (VP) to host meetings at Bank of America Leveraged Finance Conference.","No new financial data or guidance disclosed; presentation attached as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130670,"accession_number":"0001104659-25-104379","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor to sell Products & Healthcare segment; Q3 adjusted EPS $0.25","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Signed definitive agreement to sell Products & Healthcare Services segment, pivoting to pure-play home-based care.","Q3 continuing ops revenue $697.3M (+1.5% YoY); GAAP loss ($0.07)/share; adjusted EPS $0.25.","Adjusted EBITDA from continuing ops $92.2M in Q3, down 14% YoY; YTD adjusted EBITDA $284.8M up 6%.","Announced nationwide preferred provider partnership to expand home-based care reach.","Transaction expected to simplify capital deployment and focus on Patient Direct growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130669,"accession_number":"0001193125-25-233577","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Owens & Minor sells P&HS segment to Platinum Equity for $375M cash + retained equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash payment of $375 million at closing, subject to customary adjustments for working capital, net debt, and expenses.","Retains a 5% equity stake and preferred return in the P&HS business, with potential future proceeds from a divestiture.","Retains federal NOL carryforwards and other tax attributes exceeding $150 million.","Transaction expected to close near end of 2025, subject to HSR and other regulatory approvals.","Transforms Owens & Minor into a pure-play home-based care company, exiting the Products & Healthcare Services segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147229,"accession_number":"0001193125-25-208137","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor CIO Snehashish Sarkar resigns effective Sept 26, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Snehashish Sarkar, EVP and Chief Information Officer, resigns effective September 26, 2025 to pursue an external opportunity.","Sarkar joined Owens & Minor in October 2022 and served as CIO.","No successor named; the company notes his team is well-prepared to continue supporting strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147228,"accession_number":"0001193125-25-177426","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q2: GAAP loss from continuing ops $83.8M; Products & Healthcare segment classified as discontinued ops","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.","GAAP loss from continuing ops $(83.8)M vs $(6.7)M in 2Q24; adjusted net income $20.5M vs $19.3M.","Adjusted EBITDA from continuing ops $96.6M, up 6% from $91.1M.","Company in final stages of divestiture of Products & Healthcare Services segment; classified as discontinued ops.","2025 continuing ops financial outlook to be provided during 8:30 a.m. EDT earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1355801000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165846,"accession_number":"0001193125-25-137107","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Owens & Minor to redeem $1B in 10% notes due 2030 after Rotech merger termination","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Merger agreement to acquire Rotech terminated effective June 5, 2025.","Company issued notice to redeem $1,000,000,000 aggregate principal of 10.000% Senior Secured Notes due 2030.","Redemption date set for June 10, 2025; price is 100% of principal plus accrued interest.","Notes were issued April 4, 2025 to finance the now-terminated acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165845,"accession_number":"0001193125-25-135378","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Owens & Minor terminates $80M Rotech acquisition; will redeem $1B notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mutual termination of merger agreement; OMI pays $80M termination fee to Rotech.","OMI to redeem $1B notes issued April 2025 via special mandatory redemption; ends bridge loan commitments.","Regulatory clearance path deemed 'unviable' in time, expense, and opportunity.","Company to focus on deleveraging, growing Patient Direct business, and potential sale of Products & Healthcare Services.","Pesicka expresses confidence in strategy; home-based care market remains key growth area."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165844,"accession_number":"0001558370-25-007927","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Owens & Minor shareholders elect nine directors, ratify KPMG, approve say-on-pay at 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with >65M votes for each; broker non-votes of ~5.2M.","KPMG LLP ratified as independent auditor for FY2025: 69.5M for, 1.96M against.","Advisory say-on-pay approved with 63.2M for (95.2% of votes cast excluding abstentions).","Turnout: 71.6M shares voted out of 77.3M entitled (92.66%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165843,"accession_number":"0001558370-25-006844","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q1 adj EPS $0.23, revenue $2.63B; reaffirms FY guide, active on P&HS sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS $0.23 vs $0.19 YoY; GAAP net loss $(0.32) per share vs $(0.29).","Revenue $2.63B (+0.7% YoY); Patient Direct segment margin +173 bps.","Adjusted EBITDA $121.9M vs $116.3M YoY; full-year 2025 guidance reaffirmed.","Company actively engaged in potential sale of Products & Healthcare Services segment.","Integrating planned Rotech acquisition; monitoring tariff policy impacts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":2632048000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165842,"accession_number":"0001193125-25-073544","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Owens & Minor closes $1B 10% senior secured notes offering to fund Rotech acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1,000,000,000 aggregate principal of 10.000% senior secured notes due 2030 issued.","Proceeds held in escrow pending consummation of acquisition of Rotech Healthcare Holdings Inc.","Special mandatory redemption if acquisition not completed by October 6, 2025, at 100% plus accrued interest.","Notes secured by first-priority lien on escrow; after acquisition, secured by substantially all assets of company and guarantors.","Restricted covenants apply; investment grade rating would suspend most covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165841,"accession_number":"0001193125-25-071448","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Owens & Minor upsizes and prices $1B of 10.000% senior secured notes due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized to $1B aggregate principal at 10.000% interest, maturing April 15, 2030.","Offering priced at 100% of par; expected to close April 4, 2025.","Proceeds to finance Rotech acquisition; escrowed if acquisition not concurrent.","Notes secured by same collateral as existing term loan after acquisition closing.","Guaranteed jointly and severally by certain domestic subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183403,"accession_number":"0001193125-25-064131","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Owens & Minor launches $600M senior secured notes offering to finance Rotech acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Launched $600M senior secured notes due 2030 in a private placement to QIBs and non-U.S. persons.","Net proceeds, with cash and a new term loan B, will fund the Rotech acquisition, repay Rotech debt, and pay fees.","If acquisition does not close concurrently, proceeds go into escrow until conditions, including acquisition close, are met.","Notes initially secured by escrow, then by same collateral as existing senior facilities after acquisition closes.","Offering is not conditioned on acquisition completion; acquisition remains subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183402,"accession_number":"0001193125-25-058292","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Owens & Minor furnishes lender presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation dated March 20, 2025, furnished for use in meetings with lenders.","No financial results, guidance, or M&A announcements provided in the filing.","Presentation likely covers general business overview and strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183401,"accession_number":"0001558370-25-001879","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).","Total revenue $2,696M in Q4, $10,701M for FY2024; adjusted EBITDA $138M Q4, $523M FY.","Company actively engaging in discussions for potential sale of Products & Healthcare Services segment.","Board authorized share repurchase program up to $100 million; also reduced debt $244M in 2024.","2025 guidance midpoint expects double-digit adjusted EBITDA and adjusted EPS growth, improving cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":10700883000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183400,"accession_number":"0001193125-25-018849","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor: preliminary Q4 net loss ~$300M, $310M goodwill impairment; launches financing for Rotech acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 prelim rev $2.67-2.70B; net loss $(288-311)M; adj EBITDA $135-140M; adj EPS $0.52-0.55.","FY2024 prelim rev $10.67-10.70B; net loss $(355-378)M; adj EBITDA $520-525M; adj EPS $1.50-1.53.","Non-cash goodwill impairment ~$310M in Apria division from stock decline, rates, contract pricing.","Total debt reduced by over $240M in 2024; total debt ~$1.854-1.859B; net debt ~$1.805-1.810B.","Commenced financing for previously announced Rotech acquisition; expected close 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":10700883000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199984,"accession_number":"0001558370-24-014426","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor amends deferred comp plan; employer match and contributions now discretionary","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to Executive Deferred Compensation and Retirement Plan effective January 1, 2025.","Employer matching contribution now determined in its sole discretion (previously formula-based).","Employer may make non-elective contributions, vested after one year of service.","Other terms and conditions remain substantially similar to prior plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199983,"accession_number":"0001558370-24-014177","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q3 revenue up 5% to $2.7B; GAAP net loss $0.17/shr; adj EPS $0.42; debt cut $198M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue of $2.7B (+5% YoY); GAAP net loss $(13M) or $(0.17)/share.","Adjusted EBITDA $142M (+5% YoY); adjusted EPS $0.42 vs $0.44 prior year.","Total debt reduced by $198M in Q3; management expects sequential growth into Q4.","Patient Direct and Medical Distribution divisions drove top-line growth.","Adjusted net income $33.2M vs $34.1M YoY, reflecting higher interest costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":8004810000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199982,"accession_number":"0001193125-24-241069","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Owens & Minor enters $450M receivables sale facility with PNC; replaces 2020 agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $450M of accounts receivable sold on a limited-recourse basis; proceeds for general corporate purposes.","Facility amends and restates the prior receivables financing agreement dated February 19, 2020.","Scheduled termination date is October 2027; off-balance-sheet treatment under ASC 860.","PNC Bank serves as Administrative Agent; PNC Capital Markets as Structuring Agent.","Owens & Minor retains servicing duties but holds no beneficial interest in sold receivables."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199981,"accession_number":"0001193125-24-237188","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Owens & Minor receives FTC Second Request for Rotech acquisition; closing expected H1 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company and Rotech received FTC Second Request on October 11, 2024, extending HSR Act waiting period.","Closing now expected in first half of 2025, subject to regulatory approvals and other conditions.","Company continues to work constructively with FTC to satisfy the Second Request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215995,"accession_number":"0001193125-24-223254","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Owens & Minor appoints Jonathan Leon as permanent CFO effective Sept 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leon, interim CFO since June 2024, named EVP, CFO with annual salary of $550,000.","Target annual cash bonus of $298,431 under 2024 Annual Incentive Plan; annual equity target of $1.5M starting 2025.","One-time time-based RSU award with grant date fair value of $650,000.","Leon will retain corporate treasurer duties while successor search is underway.","He has been with OMI since 2017, previously SVP and Corporate Treasurer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215994,"accession_number":"0001193125-24-219607","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Owens & Minor redeems $171.3M of 4.375% Senior Notes due 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeemed all $171,322,000 aggregate principal of 4.375% Senior Notes due 2024 on September 16, 2024.","Redemption price was 100% of principal plus accrued interest up to the redemption date.","Notes are no longer outstanding and interest ceased accruing as of the redemption date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215993,"accession_number":"0001558370-24-010644","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q2 revenue up 4% to $2.7B; adjusted EPS doubles to $0.36; agrees to acquire Rotech","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.67B (+4% YoY); GAAP net loss $32M ($0.42 loss per share) vs. $28M loss last year.","Adjusted EBITDA $127M (+12% YoY); adjusted EPS $0.36 vs. $0.18, doubling year over year.","Operating cash flow $116M used to reduce debt by $71M during the quarter.","Agreement to acquire Rotech Healthcare Holdings to expand Patient Direct segment; expected close H2 2024.","Management reaffirms full-year 2024 adjusted EBITDA guidance of $515M-$545M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":5283686000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215992,"accession_number":"0001193125-24-189920","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Owens & Minor calls all $171.3M of 4.375% Senior Notes due 2024 for redemption","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Full redemption of 4.375% Senior Notes due 2024 on September 16, 2024 at 100% of principal plus accrued interest.","Aggregate principal outstanding is $171,322,000; redemption price includes accrued interest to but excluding redemption date.","Redemption is being made under the terms of the notes and indenture; no extension or exchange offered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215991,"accession_number":"0001193125-24-182569","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Owens & Minor to buy Rotech for $1.36B cash; expects ~$0.15 EPS accretion in second year","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $1.36B cash; net $1.32B after ~$40M tax benefits; ~6.3x LTM EBITDA ex-synergies.","Rotech 2023 revenue ~$750M with ~30% EBITDA margin; 4,200+ employees, ~325 locations in 46 states.","Expected close by end of 2024; subject to HSR; financed with $775M term loan B and $625M bridge.","Synergies ~$50M by end of year three; adjusted EPS neutral in first full year, accretive in second year.","Owens & Minor reaffirms 2024 full-year guidance; preliminary Q2 results reported separately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215990,"accession_number":"0001193125-24-182567","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Owens & Minor reports preliminary Q2 GAAP net loss $0.42-0.46/share, adj. EPS $0.32-$0.36; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.","One-time income tax charge of $17M ($0.22/share) from transfer pricing dispute; expected cash payment $30-$35M in H2 2024.","Full-year 2024 outlook reaffirmed: revenue $10.5-$10.9B, adj. EBITDA $550-$590M, adj. EPS $1.40-$1.70.","Adjusted EBITDA $123-$127M; operating cash flow $111-$116M; net debt reduction $68-$71M.","Full Q2 results to be released on August 2, 2024, before NYSE open."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":5283686000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235488,"accession_number":"0001193125-24-166962","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor CFO Bruni resigns at company's request; interim CFO Leon appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alexander J. Bruni resigned as EVP & CFO effective June 21, 2024, will remain until Sep 5, 2024 for transition.","Jonathan A. Leon, SVP Corporate Treasurer, appointed interim CFO; receives $250,000 one-time RSU award.","Bruni severance: 1.5x (base salary $525,000 + avg bonus 2021-23), $25,000 COBRA, plus outplacement/tax reimbursement.","Transition agreement includes non-compete, non-solicit, confidentiality, and pro-rata vesting of unvested RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235487,"accession_number":"0001558370-24-008643","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor names Jennifer Stone EVP & CHRO effective June 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Stone (53) appointed Executive Vice President & Chief Human Resources Officer.","Previously Vice President of HR, Medical Surgical Portfolio at Medtronic.","Spent over 20 years at Target Corporation in roles including Head of Talent Management.","Appointment effective June 3, 2024; no departure of prior officer disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235486,"accession_number":"0001558370-24-007697","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Owens & Minor shareholders approve plan amendment, elect nine directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected nine director nominees with majority support; votes for ranged from 66.8M to 67.4M shares.","Amendment No. 1 to 2023 Omnibus Incentive Plan approved with 64.2M for (94.7% of votes cast ex-broker non-votes).","KPMG LLP ratified as independent auditor for FY2024 with 69.2M for (97.9% of votes cast).","Advisory say-on-pay proposal approved with 66.2M for (97.9% of votes cast ex-broker non-votes).","Total shares voted: 70.7M out of 76.6M entitled (92.3% turnout)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235485,"accession_number":"0001558370-24-007615","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor promotes Snehashish Sarkar to EVP & CIO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Snehashish Sarkar (49) named Executive Vice President & Chief Information Officer effective May 9, 2024.","Mr. Sarkar joined Owens & Minor in 2022 as Senior Vice President & Chief Information Officer.","No other changes to executive officer roles disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235484,"accession_number":"0001558370-24-006589","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q1 adj EPS $0.19 (4x YoY); revenue $2.61B up 4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adj EPS $0.19 vs $0.05 YoY; GAAP net loss per share $(0.29) vs $(0.32).","Revenue $2.61B, up 4% YoY; adjusted operating income $57.4M vs $47.7M.","Gross margin expanded 79 bps; adjusted operating margin up 31 bps.","Products & Healthcare Services segment grew, invested in inventory for new customers.","Patient Direct segment delivered mid-single digit top-line growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":2612680000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235483,"accession_number":"0001193125-24-103827","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Owens & Minor EVP Dan J. Starck to retire effective May 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan J. Starck, EVP of Business Excellence, notified the Company of his retirement.","Retirement effective May 17, 2024; no successor named in the filing.","Starck's role focuses on business improvement and operational excellence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253281,"accession_number":"0001558370-24-002259","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Owens & Minor adopts PSU agreement form for 2023 Omnibus Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved form performance stock units under 2023 Omnibus Incentive Plan on Feb 28, 2024.","PSUs earn shares based on achievement of performance metrics over three-year period.","Agreement includes dividend equivalent rights, restrictive covenants, and clawback provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253280,"accession_number":"0001558370-24-001321","cik":75252,"company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Owens & Minor Q4 adjusted EPS $0.69, revenue $2.66B; full year operating cash flow $741M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income $17.8M vs loss of $58.0M; adjusted net income $53.6M vs $21.7M.","Full year adjusted EPS $1.36 vs $2.42; GAAP net loss per share $(0.54) vs $0.29.","Total debt reduced by $403M, net debt reduced by $577M; operating cash flow $741M.","Full year revenue $10.3B, up 4% from $9.96B; Q4 revenue $2.66B vs $2.55B.","Patient Direct segment outperformed; Products & Healthcare Services showed sequential improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":10333967000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":215966039.10869563,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}